Equillium Inc (STU:0FY)
€ 0.704 -0.01 (-1.4%) Market Cap: 25.02 Mil Enterprise Value: -5.26 Mil PE Ratio: 0 PB Ratio: 1.23 GF Score: 38/100

Equillium Inc at JMP Securities Life Sciences Virtual Conference Transcript

Jun 16, 2021 / 03:00PM GMT
Release Date Price: €4.89 (+0.74%)
Gobind Singh
JMP Securities LLC - Analyst

Perfect. Hi, good morning, everyone. Welcome to our JMP annual Life Sciences Conference. And I'm pleased to kick off my session with Equillium Bio. We have Bruce Steel, CEO; and Dolca Thomas, CMO, here with us today. So really glad to have you guys here. Thank you.

So they are going to tell us about their lead asset, itolizumab, targeting CD6-ALCAM pathway. It's being developed for multiple severe immuno inflammatory diseases on the heels of some new results that were recently presented from the Phase 1 EQUATE trial in first-line acute GVHD at EHA. And we will take it from there. Thank you.

Bruce Steel
Equillium, Inc. - CEO

Great. Thank you. Good morning. It's a pleasure to be here. Dolca and I are thrilled to have the opportunity to provide you the updates today. And as you mentioned, we will focus the conversation a bit on the recent EHA update that was provided by Dr. John Koreth, the lead investigator in our EQUATE study, in the first-line treatment of acute GVHD -- that was Friday at EHA. We will be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot